Addressing Barriers to Biosimilar Integration in Cancer Care
Pharmacists can expect to see more and more biosimilars developed for oncology. This activity will use cases to present clinical information on the use of biosimilars for supportive and therapeutic cancer care, discuss the barriers to biosimilar adoption, and present strategies to overcome these barriers to realize the full potential of biosimilar medicines.
After providing an overview of the regulatory framework and approval process for biosimilars, those currently on the market for use in oncology will be discussed. The faculty address approved indications, delivery methods, indication extrapolation and curative intent, the role of biosimilars in value-based oncology care, and the importance of provider and patient education strategies to enhance acceptance of biosimilar therapy. Operational barriers and strategies to overcome them will also be presented.
Agenda
Welcome and Introductions
Sandra Cuellar, Pharm.D., BCOP, Activity Chair
Overview of the regulatory framework and approval process for biosimilars
Sandra Cuellar, Pharm.D., BCOP
Clinical review of oncology biosimilars
Sandra Cuellar, Pharm.D., BCOP
Discussion of strategies to overcome barriers to integrating biosimilars into the health system
Jorge J. García, Pharm.D., M.S., M.H.A., M.B.A., FACHE
Faculty Discussion and Questions
Sandra Cuellar, Pharm.D., BCOP, and Jorge J. García, Pharm.D., M.S., M.H.A., M.B.A., FACHE
Learning Objectives
After the conclusion of this application-based educational activity, participants should be able to
- Summarize the FDA regulatory framework to evaluate biosimilars.
- Describe the application of clinical trial data and the requirements for extrapolation of indications and interchangeability of biosimilars.
- Illustrate biosimilar launch and practice implementation challenges along with best practices to overcome these barriers.
- Describe biosimilars’ role under value-based care and potential economic impact.
Target Audience
This activity was planned to meet the educational needs of pharmacists caring for oncology patients.
FormatThis online activity consists of slide presentations, active learning, an assessment, and evaluation. View the system requirements.
Disclosures
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, only the individual/s below have disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.
- Sandra Cuellar- speakers bureau for Genentech; advisory board for Coherus Biosciences, Inc.
Claim CE Within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to complete the assessment and evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
CPE Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #: 0204-000-19-425-H01-P
Release Date: February 18, 2020
Expiration Date: May 19, 2021
Activity Type:
Application-based
CE Credits:
1.5 hours
Activity Fee:
Free of charge
.jpg "Adam Brufsky")
